Mechanisms for oxidative stress in diabetic cardiovascular disease.

Obesity, metabolic syndrome, and diabetes are increasingly prevalent in Western society, and they markedly increase the risk for atherosclerotic vascular disease, the major cause of death in diabetics. Although recent evidence suggests a causal role for oxidative stress in insulin resistance, diabetes, and atherosclerosis, there is considerable controversy regarding its nature, magnitude, and underlying mechanisms. Glucose promotes glycoxidation reactions in vitro, and products of glycoxidation and lipoxidation are elevated in plasma and tissue from humans suffering from diabetes, but the exact relationships between hyperglycemia and oxidative stress are poorly understood. This review focuses on molecular mechanisms of increased oxidative stress in diabetes, the relationship of oxidant production to hyperglycemia, and the potential interaction of reactive carbonyls and lipids in oxidant generation. Using highly sensitive and specific gas chromatography-mass spectrometry, molecular signatures of specific oxidation pathways were identified in tissues of diabetic humans and animals. These studies support the hypothesis that unique reactive intermediates generated in localized microenvironments of vulnerable tissues promote diabetic damage. Therapies interrupting these reactive pathways in vascular tissue might help prevent cardiovascular disease in this high-risk population.

[1]  G. Aldini,et al.  Design, Synthesis, and Evaluation of Carnosine Derivatives as Selective and Efficient Sequestering Agents of Cytotoxic Reactive Carbonyl Species , 2009, ChemMedChem.

[2]  J. Baynes,et al.  The Metal Chelators, Trientine and Citrate, Inhibit the Development of Cardiac Pathology in the Zucker Diabetic Rat , 2009, Experimental diabetes research.

[3]  N. Borradaile,et al.  Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment , 2009, Aging cell.

[4]  Sushil K. Jain,et al.  Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. , 2009, Antioxidants & redox signaling.

[5]  H. Meštrić,et al.  Chlorination of ammonia and aliphatic amines by Cl2: DFT study of medium and substituent effects , 2009 .

[6]  S. Bornstein,et al.  Prediabetic and diabetic in vivo modification of circulating low-density lipoprotein attenuates its stimulatory effect on adrenal aldosterone and cortisol secretion. , 2008, The Journal of endocrinology.

[7]  R. Testa,et al.  Glucose "peak" and glucose "spike": Impact on endothelial function and oxidative stress. , 2008, Diabetes research and clinical practice.

[8]  N. Fukagawa,et al.  Age‐related differences in insulin‐like growth factor‐1 receptor signaling regulates Akt/FOXO3a and ERK/Fos pathways in vascular smooth muscle cells , 2008, Journal of cellular physiology.

[9]  Ping Zhang,et al.  Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development , 2008, Nature Medicine.

[10]  E. Bourdon,et al.  Oxidative stresses induced by glycoxidized human or bovine serum albumin on human monocytes. , 2008, Free radical biology & medicine.

[11]  S. Pennathur,et al.  Mass spectrometric quantification of amino acid oxidation products identifies oxidative mechanisms of diabetic end-organ damage , 2008, Reviews in Endocrine and Metabolic Disorders.

[12]  Shufeng Zhou,et al.  Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. , 2008, Archives of biochemistry and biophysics.

[13]  A. Chait,et al.  Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies , 2008, The Lancet.

[14]  R. Testa,et al.  Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients , 2008, Diabetes.

[15]  M. Davies,et al.  Mammalian heme peroxidases: from molecular mechanisms to health implications. , 2008, Antioxidants & redox signaling.

[16]  P. Sil,et al.  Protection of arsenic-induced testicular oxidative stress by arjunolic acid , 2008, Redox report : communications in free radical research.

[17]  Coral Barbas,et al.  Identification of oxidized proteins in rat plasma using avidin chromatography and tandem mass spectrometry , 2008, Proteomics.

[18]  Md. Ehsanul Hoque Mazumder,et al.  Pharmacological Evaluation of Bangladeshi Medicinal Plants for Antioxidant Activity , 2008 .

[19]  J. Sowers,et al.  Redox imbalance in diabetes. , 2007, Antioxidants & redox signaling.

[20]  J. LeLorier,et al.  Effect of ramipril on the incidence of diabetes. , 2007, The New England journal of medicine.

[21]  H. Cai,et al.  Attenuation of Angiotensin II Signaling Recouples eNOS and Inhibits Nonendothelial NOX Activity in Diabetic Mice , 2007, Diabetes.

[22]  G. Moneta,et al.  Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes , 2007 .

[23]  A. Cumaoğlu,et al.  Effects of antioxidant stobadine on protein carbonylation, advanced oxidation protein products and reductive capacity of liver in streptozotocin‐diabetic rats: Role of oxidative/nitrosative stress , 2007, BioFactors.

[24]  C. Block,et al.  Mechanisms linking obesity with cardiovascular disease , 2006, Nature.

[25]  S. Haffner,et al.  Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.

[26]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[27]  W. März,et al.  Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. , 2006, The Journal of clinical endocrinology and metabolism.

[28]  J. Heinecke,et al.  Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. , 2006, Current opinion in cardiology.

[29]  U. Smith,et al.  Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. , 2006, The New England journal of medicine.

[30]  Simon J. Walker,et al.  NADPH oxidases in cardiovascular health and disease. , 2006, Antioxidants & redox signaling.

[31]  E. Lander,et al.  Reactive oxygen species have a causal role in multiple forms of insulin resistance , 2006, Nature.

[32]  K. Griendling,et al.  Serial Review : The Role of Oxidative Stress in Diabetes mellitus Serial Review , 2006 .

[33]  R. Leibel,et al.  CCR2 modulates inflammatory and metabolic effects of high-fat feeding. , 2006, The Journal of clinical investigation.

[34]  Nimesh Mody,et al.  Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes , 2005, Nature.

[35]  H. Cai,et al.  Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Williamson,et al.  Reactive Carbonyls and Polyunsaturated Fatty Acids Produce a Hydroxyl Radical-like Species , 2005, Journal of Biological Chemistry.

[37]  A. Chait,et al.  Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. , 2004, Diabetes.

[38]  A. Chait,et al.  Human Atherosclerotic Intima and Blood of Patients with Established Coronary Artery Disease Contain High Density Lipoprotein Damaged by Reactive Nitrogen Species* , 2004, Journal of Biological Chemistry.

[39]  A. Chait,et al.  The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Michael Kinter,et al.  Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. , 2004, The Journal of clinical investigation.

[41]  S. Matsumoto,et al.  Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. , 2004, Free radical biology & medicine.

[42]  S. Hazen Myeloperoxidase and plaque vulnerability. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[43]  S. Hazen,et al.  Inflammatory and oxidative markers in atherosclerosis: Relationship to outcome , 2004, Current atherosclerosis reports.

[44]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[45]  S. Pennathur,et al.  Mechanisms of oxidative stress in diabetes: implications for the pathogenesis of vascular disease and antioxidant therapy. , 2004, Frontiers in bioscience : a journal and virtual library.

[46]  H. Hammes,et al.  Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat , 2004, Diabetologia.

[47]  M. Brownlee,et al.  Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats , 2004, Diabetologia.

[48]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[49]  E. Topol,et al.  Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.

[50]  S. Hazen,et al.  Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment , 2003, Current opinion in lipidology.

[51]  S. Hazen,et al.  Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways , 2003, Circulation.

[52]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[53]  D. O'leary,et al.  Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. , 2003, The New England journal of medicine.

[54]  S. Hazen,et al.  Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. , 2003, JAMA.

[55]  J. Heinecke Clinical trials of vitamin E in coronary artery disease: Is it time to reconsider the low-density lipoprotein oxidation hypothesis? , 2003, Current atherosclerosis reports.

[56]  H. Hammes,et al.  Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy , 2003, Nature Medicine.

[57]  E. Feldman Oxidative stress and diabetic neuropathy: a new understanding of an old problem. , 2003, The Journal of clinical investigation.

[58]  R. Collins,et al.  Heart Protection Study , 2003, The Lancet.

[59]  J. Heinecke Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. , 2003, The American journal of cardiology.

[60]  G. Gao,et al.  Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes , 2003, Diabetologia.

[61]  Daniel Steinberg,et al.  Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime , 2002, Nature Medicine.

[62]  Alan W. Stitt,et al.  The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. , 2002, Diabetes.

[63]  J. Heinecke Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. , 2002, Free radical biology & medicine.

[64]  M. Steffes,et al.  Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.

[65]  A. Schmidt,et al.  Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes , 2002, Ageing Research Reviews.

[66]  T. Metz,et al.  A Post-Amadori Inhibitor Pyridoxamine Also Inhibits Chemical Modification of Proteins by Scavenging Carbonyl Intermediates of Carbohydrate and Lipid Degradation* , 2002, The Journal of Biological Chemistry.

[67]  R. Hotchkiss,et al.  Myeloperoxidase produces nitrating oxidants in vivo , 2002 .

[68]  M. Brownlee Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.

[69]  R. Hotchkiss,et al.  NADPH oxidase of neutrophils elevates o,o'-dityrosine cross-links in proteins and urine during inflammation. , 2001, Archives of biochemistry and biophysics.

[70]  R. Stocker,et al.  Oxidants and antioxidants in atherosclerosis , 2001, Current opinion in lipidology.

[71]  J. Heinecke Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[72]  W C Willett,et al.  The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. , 2001, Archives of internal medicine.

[73]  C. Gerhardinger,et al.  Early cellular and molecular changes induced by diabetes in the retina , 2001, Diabetologia.

[74]  A. Schmidt,et al.  Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.

[75]  K. Litwak,et al.  A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. , 2001, The Journal of clinical investigation.

[76]  V. Monnier,et al.  Transition metals redox: reviving an old plot for diabetic vascular disease. , 2001, The Journal of clinical investigation.

[77]  G. FitzGerald,et al.  Effects of vitamin E on lipid peroxidation in healthy persons. , 2001, JAMA.

[78]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[79]  G. Shulman,et al.  Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver , 2001, Nature.

[80]  R. Wiklund,et al.  Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients , 2000 .

[81]  S. Hazen,et al.  Nitric Oxide Is a Physiological Substrate for Mammalian Peroxidases* , 2000, The Journal of Biological Chemistry.

[82]  H. Utsumi,et al.  High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. , 2000, Diabetes.

[83]  I. G. Fantus,et al.  Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[84]  M. Boaz,et al.  Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial , 2000, The Lancet.

[85]  F. Cipollone,et al.  Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. , 2000, Cardiovascular research.

[86]  A. Jenkins,et al.  Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions , 2000, The Journal of Biological Chemistry.

[87]  J. Baynes,et al.  Glycoxidation and lipoxidation in atherogenesis. , 2000, Free radical biology & medicine.

[88]  D. Greene,et al.  Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid. , 2000, European journal of pharmacology.

[89]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[90]  S. Haffner Coronary heart disease in patients with diabetes. , 2000, The New England journal of medicine.

[91]  A. Morris,et al.  Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. , 2000, Hypertension.

[92]  Matthew D. Davis,et al.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.

[93]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[94]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[95]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[96]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[97]  F. Gries,et al.  Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[98]  S. Pennathur,et al.  Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* , 1999, The Journal of Biological Chemistry.

[99]  R. Ross Atherosclerosis is an inflammatory disease , 1999 .

[100]  S. Cuzzocrea,et al.  A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. , 1999, Science.

[101]  S. Ihm,et al.  Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. , 1999, Metabolism: clinical and experimental.

[102]  M. Hanefeld,et al.  Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. , 1999, Diabetes care.

[103]  J. Heinecke Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[104]  C van Ypersele de Strihou,et al.  Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. , 1999, Kidney international.

[105]  G. Davı̀,et al.  In Vivo Formation of 8-Iso-Prostaglandin F2α and Platelet Activation in Diabetes Mellitus , 1999 .

[106]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[107]  J. Holloszy,et al.  Oxidized amino acids in the urine of aging rats: potential markers for assessing oxidative stress in vivo. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[108]  G. Davı̀,et al.  In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. , 1999, Circulation.

[109]  T. Miyata,et al.  Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? , 1998, Kidney international.

[110]  David M Nathan,et al.  Some answers, more controversy, from UKPDS , 1998, The Lancet.

[111]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[112]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[113]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[114]  K. Pritchard,et al.  Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[115]  Barry Halliwell,et al.  Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils , 1998, Nature.

[116]  G. King,et al.  Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus , 1997, Journal of Molecular Medicine.

[117]  D. Nathan Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. , 1998, Lancet.

[118]  J. Holloszy,et al.  Markers of protein oxidation by hydroxyl radical and reactive nitrogen species in tissues of aging rats. , 1998, The American journal of physiology.

[119]  R. Stocker,et al.  α‐Tocopherol does not inhibit hypochlorite‐induced oxidation of apolipoprotein B‐100 of low‐density lipoprotein , 1997 .

[120]  G. King,et al.  Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. , 1997, Kidney international. Supplement.

[121]  T. Lyons,et al.  Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. , 1997, The Journal of clinical investigation.

[122]  T. Lyons,et al.  Carboxymethylethanolamine, a Biomarker of Phospholipid Modification during the Maillard Reaction in Vivo * , 1997, The Journal of Biological Chemistry.

[123]  C. Kilo,et al.  Cytosolic NADH/NAD+ , free radicals, and vascular dysfunction in early diabetes mellitus , 1997, Diabetologia.

[124]  S. L. Hazen,et al.  3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. , 1997, The Journal of clinical investigation.

[125]  C van Ypersele de Strihou,et al.  Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. , 1997, Kidney international.

[126]  K. Sharma,et al.  Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. , 1997, Seminars in nephrology.

[127]  C. Semenkovich,et al.  The Mystery of Diabetes and Atherosclerosis: Time for a New Plot , 1997, Diabetes.

[128]  A. Jenkins,et al.  Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. , 1997, The Biochemical journal.

[129]  F. Hsu,et al.  Mass Spectrometric Quantification of Markers for Protein Oxidation by Tyrosyl Radical, Copper, and Hydroxyl Radical in Low Density Lipoprotein Isolated from Human Atherosclerotic Plaques* , 1997, The Journal of Biological Chemistry.

[130]  S. L. Hazen,et al.  Reactive Nitrogen Intermediates Promote Low Density Lipoprotein Oxidation in Human Atherosclerotic Intima* , 1997, The Journal of Biological Chemistry.

[131]  F. Gries,et al.  Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. , 1997, Diabetes care.

[132]  J. Heinecke Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine , 1997, BioFactors.

[133]  David H. Williams,et al.  Phosphorylation of SLP-76 by the ZAP-70 Protein-tyrosine Kinase Is Required for T-cell Receptor Function* , 1996, The Journal of Biological Chemistry.

[134]  S. Bursell,et al.  Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. , 1996, Science.

[135]  M. Matsumoto,et al.  Rage: A Novel Cellular Receptor for Advanced Glycation End Products , 1996, Diabetes.

[136]  S. Bursell,et al.  Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor , 1996, Science.

[137]  T. Lyons,et al.  The Advanced Glycation End Product, N-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (*) , 1996, The Journal of Biological Chemistry.

[138]  R. Schmidt,et al.  Effect of Aminoguanidine on the Frequency of Neuroaxonal Dystrophy in the Superior Mesenteric Sympathetic Autonomic Ganglia of Rats With Streptozocin-Induced Diabetes , 1996, Diabetes.

[139]  A. Jenkins,et al.  Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[140]  A. Pfeiffer,et al.  Diabetic microvascular complications and growth factors. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[141]  R. Bucala,et al.  Advanced glycosylation end products in diabetic renal and vascular disease. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[142]  L. Packer,et al.  alpha-Lipoic acid as a biological antioxidant. , 1995, Free radical biology & medicine.

[143]  H. Tritschler,et al.  Lipoic Acid Improves Nerve Blood Flow, Reduces Oxidative Stress, and Improves Distal Nerve Conduction in Experimental Diabetic Neuropathy , 1995, Diabetes Care.

[144]  T. Batchelder,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. , 1995, Archives of ophthalmology.

[145]  B. Margetts United Kingdom prospective diabetes study , 1995, BMJ.

[146]  L. Packer,et al.  Alpha-lipoic acid prevents buthionine sulfoximine-induced cataract formation in newborn rats. , 1995, Free radical biology & medicine.

[147]  M. Brownlee,et al.  Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.

[148]  S. Grundy,et al.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[149]  J. Heinecke,et al.  Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. , 1994, The Journal of biological chemistry.

[150]  A. Chait,et al.  Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. , 1994, The Journal of clinical investigation.

[151]  A. Daugherty,et al.  Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. , 1994, The Journal of clinical investigation.

[152]  H. Ischiropoulos,et al.  Oxidative chemistry of peroxynitrite. , 1994, Methods in enzymology.

[153]  B. Halliwell,et al.  Detection of hydroxyl radicals by aromatic hydroxylation. , 1994, Methods in enzymology.

[154]  D. Steinberg,et al.  Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[155]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[156]  B. Ames,et al.  Oxidants, antioxidants, and the degenerative diseases of aging. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[157]  R. Bucala,et al.  Lipid advanced glycosylation: pathway for lipid oxidation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[158]  J. Baynes,et al.  Formation of o-tyrosine and dityrosine in proteins during radiolytic and metal-catalyzed oxidation. , 1993, The Journal of biological chemistry.

[159]  T. Lyons,et al.  Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. , 1993, The Journal of clinical investigation.

[160]  J. Nyengaard,et al.  Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.

[161]  T. Lyons,et al.  Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging a , 1992, Annals of the New York Academy of Sciences.

[162]  J. Baynes,et al.  o‐Tyrosine and Dityrosine Concentrations in Oxidized Proteins and Lens Proteins with Age a , 1992, Annals of the New York Academy of Sciences.

[163]  J. Goldstein,et al.  Koch's postulates for cholesterol , 1992, Cell.

[164]  V. Monnier,et al.  Pentosidine Formation in Skin Correlates With Severity of Complications in Individuals With Long-Standing IDDM , 1992, Diabetes.

[165]  H. Hammes,et al.  Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[166]  J. Baynes,et al.  Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. , 1991, The Journal of biological chemistry.

[167]  D. Steinberg,et al.  Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.

[168]  S. Wolff,et al.  Autoxidative Glycosylation and Possible Involvement of Peroxides and Free Radicals in LDL Modification by Glucose , 1990, Diabetes.

[169]  J L Witztum,et al.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.

[170]  R. Dean,et al.  Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. , 1988, The Biochemical journal.

[171]  M. Haberland,et al.  Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. , 1988, Science.

[172]  T. Carew,et al.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[173]  A. Ooshima,et al.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[174]  A. Cerami,et al.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.

[175]  S. Young,et al.  Probucol inhibits oxidative modification of low density lipoprotein. , 1986, The Journal of clinical investigation.

[176]  A. Chait,et al.  Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. , 1984, The Journal of clinical investigation.

[177]  D. Morel,et al.  Endothelial and Smooth Muscle Cells Alter Low Density Lipoprotein In Vitro by Free Radical Oxidation , 1984, Arteriosclerosis.

[178]  J L Witztum,et al.  Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[179]  S. Klebanoff Oxygen metabolism and the toxic properties of phagocytes. , 1980, Annals of internal medicine.

[180]  M. Brown,et al.  Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[181]  R. Clark,et al.  The neutrophil: Function and clinical disorders , 1978 .